EU Clinical Trial 2018-002292-18

CT air-trapping characterization for the early identification of Benralizumab responders among eosinophilic asthma patients  May 24, 2019

Main objective of the trial: The primary objective of this study is to determine the prognostic value (sensitivity and specificity) of air-trapping measures (Expiratory/Inspiratory Mean Lung Density) detected via quantitative thoracic computed tomography at baseline for improvement in exacerbation rate (0 to 1 non-severe exacerbation during follow-up versus all others) at 52 weeks among eosinophilic patients with chronic airway disorders treated with Benralizumab.


Fasenra (benralizumab)

JSON preview

Similar records


Source:  EMA Last updated:  May 30, 2019

From, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.